Office-Based, Single-Sided, Low-Field MRI-Guided Prostate Biopsy

Poorvi Satya; John Adams Jr; Srirama S Venkataraman; Dinesh Kumar; Ram Narayanan; Aleksandar Nacev; Joseph N Macaluso Jr

doi:10.7759/cureus.25021

Office-Based, Single-Sided, Low-Field MRI-Guided Prostate Biopsy

Cureus. 2022 May 15;14(5):e25021. doi: 10.7759/cureus.25021. eCollection 2022 May.

Authors

Poorvi Satya¹, John Adams Jr², Srirama S Venkataraman³, Dinesh Kumar³, Ram Narayanan⁴, Aleksandar Nacev⁴, Joseph N Macaluso Jr⁵

Affiliations

¹ Operations, Mailman School of Public Health, Columbia University, New York, USA.
² Urology, Mississippi Urology Clinic, PLLC., Jackson, USA.
³ Operations, Promaxo Inc., Oakland, USA.
⁴ Engineering, Promaxo Inc., Oakland, USA.
⁵ Urology, Louisiana State University Health Foundation, New Orleans, USA.

Abstract

This paper describes the workflow of transperineal prostate biopsy (TBx) using the single-sided, low-field Promaxo MRI system (Promaxo Inc., Oakland, California, United States) operating at a field strength ranging between 58 and 74 millitesla (mT). Prostate cancer (PCa) is the leading cause of cancer-related death and the second most frequently diagnosed cancer in men. Systematic biopsy (SBx) with 12-14 cores is the preferred standard of care procedure. The blinded approach of SBx, however, results in several shortcomings, including high rates of false negatives and increased infection rates due to the transrectal approach. The evolution of clinical use and scientific research using different prostate biopsy modalities is discussed, including the potential for the Promaxo MRI system to mitigate logistical constraints often associated with standard magnetic resonance (MR)-guided biopsy through the utilization of an office-based, low-field MRI.

Keywords: low-field mri; male urology; mr-guided biopsy; mri; office-based mri; prostate biopsy; prostate cancer; targeted prostate biopsy; urology.